NIH Research Grant Awarded to Foster the Development of Oral IL-23 Receptor Antagonists for IBD

NIH Research Grant Awarded to Foster the Development of Oral IL-23 Receptor Antagonists for IBD
0
(0)

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute that is part of the National Institute of Health (NIH), recently granted a Phase 1 Small Business Innovation Research Grant to Protagonist Therapeutics. The grant will foster the development of a new drug for the treatment of Inflammatory Bowel Disease (IBD). The drug is an orally administered peptide that blocks interleukin-23 (IL-23) receptor activity, since it was shown that IL-23 and IL-23 receptor levels are increased in several chronic inflammatory disorders and orchestrate intestinal inflammation via multiple pathways.

Efficacy was demonstrated in rodent models and now the Research Grant will help Protagonist Therapeutics to develop a human drug that will effectively target the intestinal tissue (and hence decrease its systemic effects), and can therefore be administered in high doses.

David Y. Liu, PhD, chief scientific officer of Protagonist, commented in a news release, “We are very pleased to receive this grant, which provides further validation of the strong potential offered by our technology platform for the creation of novel, orally stable peptide drugs. Through this award, the reviewers also recognize the considerable benefit, which could be provided for the treatment of inflammatory bowel disease through a first-in-class therapeutic targeting the IL-23/Th17 pathway. The [Small Business Innovation Research] program at NIH plays a vital role in helping companies develop new technology and products that serve important U.S. health care needs.”

Dinesh Patel, PhD, president and CEO of Protagonist added, “Since IBD represents local inflammation of the intestinal tissue, an ideal therapeutic would act within the confines of the intestine for enhanced efficacy while minimizing systemic bioavailability for enhanced safety. A drug with these characteristics would have the potential to transform the treatment of IBD by providing safe, effective and durable therapy for chronic treatment. This award will help us develop a new oral asset for IBD stemming from Protagonist’s proprietary technology platform that acts specifically to inhibit the IL-23/Th17 pathway. In the long run, it is critical to develop safe and effective drugs working through different mechanisms to serve unmet medical needs for chronic illnesses like IBD.”

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • ABX464
  • Abivax, ABX464 , ulcerative colitis
  • microscopic colitis
  • IBD treatment COVID-19

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?